Seborrheic Dermatitis Across Skin Tones and Long-Term Disease Burden

This episode, titled Seborrheic Dermatitis Across Skin Tones and Long-Term Disease Burden, features dermatology experts discussing the following critical questions:

How might presentation of SD differ in various skin tones? What challenges do you encounter when diagnosing SD in patients with skin color?

In your experience, what long-term complications arise when SD is inadequately treated or remains uncontrolled over time?

Led by the Christopher Bunick MD, PhD, Benjamin Ungar, MD, examined seborrheic dermatitis (SD) presenting differently across skin tones, with erythema appearing less visibly red and more violaceous, gray, or hyperpigmented in patients with darker skin. Scale may be subtler or appear thicker and more adherent, which can complicate visual recognition of active inflammation. These variations increase the risk of misdiagnosis or delayed diagnosis, particularly when SD overlaps with conditions such as psoriasis, tinea, or atopic dermatitis. Post-inflammatory hyperpigmentation or hypopigmentation is also more common in skin of color and may persist even after inflammation improves, further affecting patient perception of disease severity. When SD remains inadequately treated, chronic inflammation can lead to frequent flares and progressive involvement of additional body sites. Patients may also experience worsening pruritus, barrier disruption, and increased susceptibility to secondary infections. Over time, the visible and recurrent nature of uncontrolled SD can significantly impair quality of life and contribute to psychosocial distress and treatment fatigue.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, Early Identification and Age-Specific Treatment Goals in Seborrheic Dermatitis, panelists will continue their discussion and highlight the importance of early identification of seborrheic dermatitis to prevent chronic inflammation, recurrent flares, and long-term disease burden. It also compares treatment goals in pediatric versus adult patients, emphasizing how age-related considerations and comorbidities influence therapeutic decision-making and long-term management strategies.